Susquehanna International Group, LLP Sellas Life Sciences Group, Inc. Transaction History
Susquehanna International Group, LLP
- $641 Billion
- Q4 2024
A detailed history of Susquehanna International Group, LLP transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 21,000 shares of SLS stock, worth $26,670. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,000
Previous 1,456,200
98.56%
Holding current value
$26,670
Previous $1.82 Million
98.85%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding SLS
# of Institutions
38Shares Held
7.08MCall Options Held
1.8MPut Options Held
49.7K-
Vanguard Group Inc Valley Forge, PA2.29MShares$2.91 Million0.0% of portfolio
-
Anson Funds Management LP Dallas, TX1.19MShares$1.51 Million0.16% of portfolio
-
Geode Capital Management, LLC Boston, MA734KShares$931,6030.0% of portfolio
-
Brooklyn Fi, LLC New York, NY595KShares$755,5470.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il485KShares$616,3520.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $26.1M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...